Equity awards to Delcath Systems (DCTH) chief medical officer detailed

Rhea-AI Filing Summary

Delcath Systems chief medical officer Vojo Vukovic received new equity awards. On February 17, 2026, he was granted stock options for 56,500 shares at an exercise price of $0.00 per share and 28,250 restricted stock units (RSUs).

The options vest at a rate of one‑thirty‑sixth per month starting on February 17, 2026, as long as he remains an employee under the company’s 2020 Omnibus Equity Incentive Plan. Each RSU represents a contingent right to one share of common stock, with one‑third vesting on February 17, 2027 and the remaining two‑thirds in equal annual installments over the following two years, subject to continued service.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Vukovic Vojo

Role CHIEF MEDICAL OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	56,500	$0.00	--
Grant/Award	Restricted Stock Units	28,250	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 56,500 shares (Direct); Restricted Stock Units — 28,250 shares (Direct)

Footnotes (1)

1. The option will vest and become exercisable at the rate of one-thirty-sixth (1/36th) per month with the first such vesting to occur on February 17, 2026 and monthly thereafter for so long as the reporting person remains an employee of Delcath Systems, Inc. (and subject to the terms and conditions of the Delcath Systems, Inc. 2020 Omnibus Equity Incentive Plan, as amended). Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock. Represents an RSU award, one-third of which shall vest on February 17, 2027 with the remaining 2/3 two-thirds of the RSUs vesting in equal annual installments over the following two years. The vesting of the RSUs is subject to the Reporting Person's continuous service through each such vesting date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vukovic Vojo

(Last) (First) (Middle)

C/O DELCATH SYSTEMS, INC.

566 QUEENSBURY AVENUE

(Street)

QUEENSBURY NY 12804

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
DELCATH SYSTEMS, INC. [ DCTH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF MEDICAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$9.4	02/17/2026		A		56,500		(1)	02/17/2036	Common Stock	56,500	$0	56,500	D
Restricted Stock Units	(2)	02/17/2026		A		28,250		(3)	(3)	Common Stock	28,250	$0	28,250	D

Explanation of Responses:

1. The option will vest and become exercisable at the rate of one-thirty-sixth (1/36th) per month with the first such vesting to occur on February 17, 2026 and monthly thereafter for so long as the reporting person remains an employee of Delcath Systems, Inc. (and subject to the terms and conditions of the Delcath Systems, Inc. 2020 Omnibus Equity Incentive Plan, as amended).

2. Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock.

3. Represents an RSU award, one-third of which shall vest on February 17, 2027 with the remaining 2/3 two-thirds of the RSUs vesting in equal annual installments over the following two years. The vesting of the RSUs is subject to the Reporting Person's continuous service through each such vesting date.

	/s/ David Hoffman, Attorney-in-Fact	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did Delcath Systems (DCTH) report for Vojo Vukovic?

Delcath Systems reported equity awards to chief medical officer Vojo Vukovic. He received 56,500 stock options and 28,250 restricted stock units on February 17, 2026, reflecting compensation rather than an open-market stock purchase or sale.

How many stock options were granted to the Delcath Systems (DCTH) CMO?

Vojo Vukovic was granted 56,500 stock options with an exercise price of $0.00 per share. These options vest monthly in equal one‑thirty‑sixth installments beginning February 17, 2026, contingent on his continued employment with Delcath Systems.

What restricted stock unit (RSU) award did Delcath Systems (DCTH) grant?

Delcath Systems granted 28,250 restricted stock units to its chief medical officer. Each RSU represents a contingent right to receive one share of common stock, subject to a multi‑year vesting schedule tied to continued service with the company.

What is the vesting schedule for Delcath Systems (DCTH) stock options granted to the CMO?

The stock options vest and become exercisable at a rate of one‑thirty‑sixth per month. Vesting begins on February 17, 2026 and continues monthly thereafter, as long as Vojo Vukovic remains an employee under the company’s 2020 Omnibus Equity Incentive Plan.

How do the Delcath Systems (DCTH) RSUs granted to the CMO vest over time?

One‑third of the 28,250 RSUs vest on February 17, 2027. The remaining two‑thirds vest in equal annual installments over the following two years, and each vesting date requires the executive’s continuous service with Delcath Systems.

Does the Delcath Systems (DCTH) Form 4 show an open-market stock purchase or sale?

The Form 4 shows equity awards, not open‑market trades. Vojo Vukovic acquired 56,500 stock options and 28,250 RSUs as grants with a transaction code indicating grant or award, rather than buying or selling shares in the market.